Management is buying/committing capital at a price it says the market itself just set against it — cheapness measured ag
The model's full reasoning — Q2 2021 call → NOWe need answer only YES or NO. Need analyze transcript. Need determine if management describes deliberately taking on more own economic exposure because believes outside world mispricing what it already has. Need both halves: mispricing anchored concrete, and action with resources in motion. Let's read transcript. Management discusses results, COVID, base business recovery, PAMA, investments, M&A, buybacks? Need look for buyback or repurchase? They mention cash provided by operations, investments, M&A. No explicit share repurchase? Let's search. Transcript: "We continue to execute on our M&A strategy. In June, we announced the completion of our acquisition of an outreach laboratory services business of Mercy Health..." That's acquisition of another business, not own exposure. They talk about investments in growth. No mention of buyback. They discuss PAMA and MedPAC report, but that's regulatory, not mispricing of company assets. They discuss "power and affordable care campaign" etc. Question asks: "does management describe the company DELIBERATELY TAKING ON MORE OF ITS OWN ECONOMIC EXPOSURE BECAUSE IT BELIEVES THE OUTSIDE WORLD IS CURRENTLY MISPRICING WHAT IT ALREADY HAS" - i.e., outsiders valuing company or assets too low, and company responding by acquiring/retaining/concentrating exposure. Need see if any statement like "our stock is undervalued" or "we are buying back shares because..." No. They mention "we are well positioned", "strong quarter", "faster than expected recovery", "outlook". No mispricing claim. They discuss PAMA: "MedPAC report estimates Medicare spending for top 100 tests could increase by 10% to 15% over current rates based on certain rate and volume assumptions." That's about rates, not company value. They are challenging PAMA, but not about own assets being undervalued. They discuss investments: "we continue to make progress on our two point strategy... We continue to execute on our M&A strategy... acquisition of outreach laboratory services business of Mercy Health... with this acquisition we are on our way to grow our base business revenues approximately 2% from accretive strategic acquisitions this year..." That's acquiring another business, not own exposure. They don't say it's undervalued. They say "accretive strategic acquisitions" but no mispricing. They discuss "we have engaged with businesses... working with partners..." No.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| CTHR | Charles & Colvard, Ltd. | Q1 2023 | 2022-11-06 | F |
| SBGI | Sinclair Broadcast Group, Inc. | Q3 2022 | 2022-11-02 | C |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
TWO · Q2 2022 → YESThe question is whether management describes the company deliberately taking on more of its own economic exposure because it believes the outside world is currently mispricing what it already has. YES Management anchors the mispricing to concrete, verifiable levels: mortgage spreads at “historically wide” levels (125–150 bp ZV/OAS, far above the non-QE average and the March 31 levels), RMBS coupons now trading at a wide range (2 %–5.5 %) with 300 bp “out-of-the-money” low-coupon pools and 97 bp OAS–ZV spread differential on higher-coupon names.
ESEA · Q4 2022 → YESThe question is whether management describes the company deliberately taking on more of its own economic exposure because it believes the outside world is currently mispricing what it already has. YES Management anchors the undervaluation claim to a concrete, verifiable figure: their own estimate of the fleet’s market value at $666 million (derived from charter-adjusted values and market changes, incorporating the Aegean Express incident), which produces a net asset value of $344 million or >$48 per share.
WD · Q2 2022 → YESThe question is whether management describes the company deliberately taking on more of its own economic exposure because it believes the outside world is currently mispricing what it already has. YES Management anchors the undervaluation claim to a concrete benchmark: CoStar trades at ~30x EBITDA while W&D trades at under 10x despite identical revenue and EBITDA growth rates over 5–10 years. They explicitly state there is “plenty of multiple expansion available to W&D.